Category: 1239463-43-4

1239463-43-4, 5-Bromo-6-fluoroisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a stirred solution of 5-bromo-6-fluoroisoquinoline (43.9 g, 194 mmol) in DCM (880 mL) acetyl chloride (14.49 mL, 204 mmol) was dropped at RT and the solution was stirred for 60 min. The solution was cooled to -78C (yellow suspension) and then a solution of tert-butyl((1 – methoxyviny)oxy)dimethylsilane (38.4 g, 204 mmol) in DCM (220 mL) was added in one portion. The resulting yellow solution was stirred at -78C for 1 and then allowed to warm to rt overnight. 2N aqueous HCl was added and the reaction mixture was stirred for 10 min. The organic layer was separated and washed with brine (2x). The combined organic layers were dried with sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was dissolved in diethyl ether, charcoal was added and the mixture was filtrated through a pad of celite. The solvent was evaporated and the crude product was dried under high vacuo overnight to yield the title compound (70.6 g) which was used without further purification. UPLC-MS: MS 342.2/344.2 (M+H*) ; UPLC rt 1.05 min., 1239463-43-4

The synthetic route of 1239463-43-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; BEHNKE, Dirk; CARCACHE, David; ERTL, Peter; KOLLER, Manuel; ORAIN, David; WO2014/30128; (2014); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1239463-43-4,5-Bromo-6-fluoroisoquinoline,as a common compound, the synthetic route is as follows.

To a solution of 5-bromo-6-fluoroisoquinoline (1.0 g, 4.4 mmol) in acetic acid (20.0 mL) at room temperature was added sodium tetrahydroborate (592.0 mg, 15.65 mmol) portionwise. The mixture was stirred at room temperature for 16 h, and then concentrated. The residue was diluted with CH2Cl2 and washed with aqueous Na2CO3 (2 M). The separated organic phase was dried over anhydrous Na2SO4, filtered and concentrated to give a yellow oil which was used directly in the next step without further purification. LCMS calculated for C9H10BrFN (M+H)+ m/z=230.0; found 230.1., 1239463-43-4

1239463-43-4 5-Bromo-6-fluoroisoquinoline 68757738, aisoquinoline compound, is more and more widely used in various fields.

Reference£º
Patent; Incyte Corporation; Liu, Kai; Pan, Jun; Sokolsky, Alexander; Vechorkin, Oleg; Ye, Hai Fen; Ye, Qinda; Yao, Wenqing; (75 pag.)US2018/72718; (2018); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1239463-43-4,5-Bromo-6-fluoroisoquinoline,as a common compound, the synthetic route is as follows.

Step 1. methyl 2-(2-acetyl-5-bromo-6-fluoro-1,2-dihydroisoquinolin-1-yl)acetate To a stirred solution of 5-bromo-6-fluoroisoquinoline (43.9 g, 194 mmol) in DCM (880 mL) acetyl chloride (14.49 mL, 204 mmol) was dropped at RT and the solution was stirred for 60 min. The solution was cooled to -78 C. (yellow suspension) and then a solution of tert-butyl((1-methoxyvinyl)oxy)dimethylsilane (38.4 g, 204 mmol) in DCM (220 mL) was added in one portion. The resulting yellow solution was stirred at -78 C. for 1 h and then allowed to warm to rt overnight. 2N aqueous HCl was added and the reaction mixture was stirred for 10 min. The organic layer was separated and washed with brine (2*). The combined organic layers were dried with sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was dissolved in diethyl ether, charcoal was added and the mixture was filtrated through a pad of celite. The solvent was evaporated and the crude product was dried under high vacuo overnight to yield the title compound (70.6 g) which was used without further purification. UPLC-MS: MS 342.2/344.2 (M+H+); UPLC rt 1.05 min., 1239463-43-4

As the paragraph descriping shows that 1239463-43-4 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; BEHNKE, Dirk; CARCACHE, David; ERTL, Peter; KOLLER, Manuel; ORAIN, David; US2014/57902; (2014); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem